Behavior therapy and sibutramine for the treatment of adolescent obesity - A randomized controlled trial

被引:238
作者
Berkowitz, RI
Wadden, TA
Tershakovec, AM
Cronquist, JL
机构
[1] Univ Penn, Weight & Eating Disorders Program, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Dept Psychiat, Philadelphia, PA 19104 USA
[3] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2003年 / 289卷 / 14期
关键词
D O I
10.1001/jama.289.14.1805
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Adolescent obesity is becoming a national public health problem. Weight-loss medications including sibutramine facilitate weight control in adults and could be used with obese adolescents in combination with behavior therapy (BT). Objective To examine whether increased weight loss in obese adolescents is induced when sibutramine is added to a family-based, behavioral weight control program. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial, consisting of 82 adolescents aged 13 to 17 years with a body mass index (BMI) of 32 to 44 conducted from March 1999 to August 2002 at a university-based clinic for 6 months, followed by open-label treatment during months 7 to 12. Interventions For the first 6 months, participants received either BT and sibutramine or BT and placebo. From months 7 to 12, all participants received sibutramine in open-label treatment. Main Outcome Measures Percentage change in BMI; systolic and diastolic blood pressure and pulse; and hunger. Results In intention-to-treat analysis at month 6, participants in the BT and sibutramine group lost a mean (SD) of 7.8 kg (6.3 kg) and had an 8.5% (6.8%) reduction in BMI, which was significantly more than weight loss of 3.2 kg (6.1 kg) and reduction in BMI of 4.00% (5.4%) in the BT and placebo group. Significantly greater reductions in hunger (P=.002) also were reported by participants who received BT and sibutramine. From months 7 to 12, adolescents initially treated with sibutramine gained 0.8 kg (10.5 kg) with continued use of the medication, whereas those who switched from placebo to sibutramine lost an additional 1.3 kg (5.4 kg). Medication. dose was reduced (n=23) or discontinued (n=10) to manage increases in blood-pressure, pulse rate, or other symptoms. Conclusions The addition of sibutramine to a comprehensive behavioral program induced significantly more weight loss than did BT and placebo. Until more extensive safety and efficacy data are available, medications for weight loss should be used only on an experimental basis in adolescents and children.
引用
收藏
页码:1805 / 1812
页数:8
相关论文
共 40 条
  • [1] *ABB LAB, 2002, MER SIB HYDR
  • [2] Double-blind randomized placebo-controlled trial of sibutramine
    Bray, GA
    Ryan, DH
    Gordon, D
    Heidingsfelder, S
    Cerise, F
    Wilson, K
    [J]. OBESITY RESEARCH, 1996, 4 (03): : 263 - 270
  • [3] Callaway CW, 1988, ANTHROPOMETRIC STAND, P39
  • [4] *CDCP, 2002, EP INF 2002 DAT STAT
  • [5] Cohen J, 1998, STAT POWER ANAL BEHA
  • [6] Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial
    Davidson, MH
    Hauptman, J
    DiGirolamo, M
    Foreyt, JP
    Halsted, CH
    Heber, D
    Heimburger, DC
    Lucas, CP
    Robbins, DC
    Chung, J
    Heymsfield, SB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03): : 235 - 242
  • [7] *EUR AG EV MED PRO, 2002, COMM PROP MED PROD O
  • [8] Glaser NS, 1998, WESTERN J MED, V168, P11
  • [9] Goldfield G. S., 2002, Handbook of obesity treatment, P532
  • [10] Haddock C. Keith, 1994, Annals of Behavioral Medicine, V16, P235